Zidovudine

NIOSH table

Table 2 Non-antineoplastic — eligible for a documented Assessment of Risk.

AHFS classification

8:18.08.20 HIV nucleoside and nucleotide reverse transcriptase inhibitors

This page reports this drug’s status on the NIOSH List of Hazardous Drugs in Healthcare Settings, 2024. It is not a hazard determination and not a handling instruction. Your facility makes its own Assessment of Risk under USP <800>. Package-insert content changes when the manufacturer revises the label — always screen the current insert before relying on it.